Breakthrough in Nanovesicle Research for Melanoma Treatment

Researchers at the Shenzhen Campus of Sun Yat-sen University have made significant progress in developing a new treatment for melanoma using nanovesicles. Their innovative approach combines immune checkpoint inhibitors with advanced delivery systems to enhance the efficiency of antigen presentation and direct tumor suppression. The study demonstrates the potential of these nanovesicles in promoting DC-mediated priming, T cell activation, and direct tumor suppression, ultimately reversing the immunosuppressive microenvironment of melanoma.

Key Takeaways:

• The researchers have developed a novel approach to treat melanoma by using wild Glycyrrhiza uralensis Fisch roots-derived nanovesicles (GC NV) as effective inhibitors of melanoma proliferation.
• The GC NV exert their anti-melanoma activity through the intracellular delivery of encapsulated miRNA (miR2916) and bioactive molecules (isoliquiritigenin), as well as a STING agonist DMXAA.
• The researchers have also demonstrated that chemical modification can be used to install PD-L1 antibodies on the membrane surface of these GC NV, imparting selectivity for tumor cells.
• Combining DMXAA encapsulation with surface-displayed PD-L1 antibodies creates vesicles (GP@DMX NV) that promote DCs maturation and elicit CD8 T cell response.
• The multifunctional GP@DMX NV have been shown to reverse the immunosuppressive microenvironment of melanoma and significantly enhance the immunotherapeutic potential of immune checkpoints.
• The researchers have published their findings in a peer-reviewed paper titled "PD-L1 antibody-modified plant-derived nanovesicles carrying a STING agonist for the combinational immunotherapy of melanoma" in the journal Biomaterials.

Statistics:

• The researchers used a STING agonist DMXAA, which has been shown to induce significant anti-cancer activity.
• The GC NV were found to be effective inhibitors of melanoma proliferation, with an IC50 value of 10.4 ± 1.8 μM.
• The GP@DMX NV were shown to promote DCs maturation and elicit CD8 T cell response, with a significant enhancement in immunotherapeutic potential.
• The study was conducted by a team of researchers from the Shenzhen Campus of Sun Yat-sen University, including Xinrui Yang, Zhanxue Xu, Xingyu Lu, and other co-authors.

Sources:

• Yang, X., et al. (2025). PD-L1 antibody-modified plant-derived nanovesicles carrying a STING agonist for the combinational immunotherapy of melanoma. Biomaterials, 322, 123396. doi: 10.1016/j.biomaterials.2025.123396
• Elsevier Sci Ltd. (2025). Biomaterials. Retrieved from
• Shenzhen Campus of Sun Yat-sen University. (2025). School of Pharmaceutical Sciences. Retrieved from